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Abstract: The mitral valve is a complex multilayered structure populated 
by fibroblast-like cells, valvular interstitial cells (VIC) which are 
embedded in an extracellular matrix (ECM) scaffold and are submitted to 
the mechanical deformations affecting valve at each heartbeat, for an 
average of 40 million times per year. Myxomatous mitral valve (MMV) is 
the most frequent heart valve disease characterized by disruption of 
several valvular structures due to alterations of their ECM preventing 
the complete closure of the valve resulting in symptoms of prolapse and 
regurgitation. VIC and their ECM exhibit reciprocal dynamic processes 
between the mechanical signals issued from the ECM and the modulation of 
VIC phenotype responsible for ECM homeostasis of the valve. Abnormal 
perception and responsiveness of VIC to mechanical stress may induce an 
inappropriate adaptative remodeling of the valve progressively leading to 
MMV. To investigate the response of human VIC to mechanical strain and 
identify the molecular mechanisms of mechano-transduction in these cells, 
a cyclic equibiaxial elongation of 14% at the cardiac frequency of 1.16 
Hz was applied to VIC by using a Flexercell-4000T™ apparatus for 
increasing time (from 1h to 8h). We showed that cyclic stretch induces an 
early (1h) and transient over-expression of TGFβ2 and αSMA. CTGF, a 
profibrotic growth factor promoting the synthesis of ECM components, was 
strongly induced after 1 and 2 h of stretching and still upregulated at 8 
h. The mechanical stress-induced CTGF up-regulation was dependent on 
RhoC, but not RhoA, as demonstrated by siRNA-mediated silencing 
approaches, and further supported by evidencing RhoC activation upon cell 
stretching and suppression of cell response by pharmacological inhibition 
of the effector ROCK1/2. It was also dependent on the MEK/Erk1/2 pathway 
which was activated by mechanical stress independently of RhoC and ROCK. 
Finally, mechanical stretching induced the nuclear translocation of 
myocardin related family factor MRTF-A which forms a transcriptional 
complex with SRF to promote the expression of target genes, notably CTGF. 
Treatment of stretched cultures with inhibitors of the identified 
pathways (ROCK1/2, MEK/Erk1/2, MRTF-A translocation) blocked CTGF 
overexpression and abrogated the increased MRTF-A nuclear translocation. 
CTGF is up-regulated in many pathological processes involving 
mechanically challenged organs, promotes ECM accumulation and is 
considered as a hallmark of fibrotic diseases. Pharmacological targeting 










We are most pleased to submit to JMCC our manuscript # 12086R1 "Mechanical strain induces a pro-
fibrotic phenotype in human mitral valvular interstitial cells through RhoC/ROCK/MRTF-A and Erk1/2 
signaling pathways" revised according to the comments of the reviewer 3.  The main requirement of the 
reviewer was to consolidate the hypothesis of the independence of two signaling pathways regulating 
CTGF expression upon mechanical stretching. We had no other way than to carry out the experiment to 
satisfy this request, although you mentioned that performing new experiments was not necessary. These 
results do not lengthen much the manuscript but strengthen it. Therefore, we took the liberty to include 
these data in the form of two small panels in figure 3 and to briefly describe them. We can however 
remove these two small panels and information, as per your decision. 
 
We hope to have adequately addressed the last concerns of the reviewer and we thank you for your 
consideration. 
 




Prof. A. Colige 
Laboratory of Connective Tissues Biology 





Response to the reviewer JMCC 12086 R1 
We thank the reviewer for the positive recommendation for publication of our manuscript and the 
relevant suggestion to consolidate one of our hypotheses. 
Reviewer #3: The present study investigated how the mitral valvular interstitial cells (VIC) respond to 
mechanical stress and subsequently initiate pathways for extracellular matrix synthesis. Human VIC were 
subjected to cyclic stretching and CTGF, the key ECM mediator, was found upregulated. Mechanism 
study revealed that RhoC/ROCK and MEK/Erk pathways independently contribute to MRTF-A nuclear 
translocation, which works together with SRF to promote transcription of ECM genes. In summary, the 
use of human VIC and in vitro mechanical strain provide a new approach for the study of valvular 
diseases. The manuscript is suitable for publication if the following concerns are solved. 
1. In fig.3, the authors demonstrated that activation of MEK/ERK pathway by cyclic stretching is 
independent of RhoC/ROCK pathway. The RhoC knockdown experiment is not sufficient to exclude the 
involvement of ROCK in this MEK/ERK activation process since ROCK can be turned on by many other 
factors. Therefore, application of ROCK inhibitor (Y27632) may consolidate the hypothesis that there is a 
cross-talk between ROCK and MEK/ERK pathways during mechanical stress response in VIC. 
To answer the reviewer’s concern regarding the involvement of ROCK in the MEK/ERK activation process, 
we complied with the suggestion to use the ROCK inhibitor Y27632. As shown in the figure below, the 
tratmpent by Y27632 did not impair the MEK/ERK activation pathway by mechanical stretching in 
concordance with the RhoC silencing experiment. The efficiency of Y27632 was assessed by checking the 
inhibition of phosphorylation of myosin light chain, a known ROCK substrate (data not shown). 
 
VIC were submitted or not to mechanical stretching for 10 min using the 
experimental procedure described in the manuscript, in control conditions or after 
a 1 h pre-treatment with Y27632 (5µM). A: western-blot analysis of phospho-Erk 
(p-Erk) in static and stretched cells in absence (ctrl) and presence of Y27632. B: 
quantification of p-Erk relative to -tubulin used as protein load control 





These results have been added in the figure 3 (G & H) of the revised manuscript p 13-14 and briefly 
described in the text p 12 line 26-27. 
 
2. The authors used recombinant CTGF to demonstrate its specific role in sensing mechanical stress and 
in the regulation of ECM genes expression (fig. 6). However, the expression levels of ECM genes were not 
changed when endogenous TCGF were increased after stress stretching (table S3). Why the effects of 
extra versus endogenous TCGF are different? The controversial findings should be discussed. 
Our aim by using recombinant CTGF on VIC was to verify if these cells are able to respond to it, what had 
never been investigated before, to our best knowledge. We found that they indeed respond to CTGF very 
similarly to what was previously observed with skin fibroblasts, by an increased expression of type I 
collagen, fibromodulin, CTGF itself and CYR61. In this experimental setting, the commercially available 
recombinant CTGF is an 11 kDa peptide, of undisclosed sequence and location in the native CTGF and 
with a biological activity similar to that of CTGF. It was administered in one shot at 30ng/ml to VIC in 
culture. By contrast, during the stretching experiments, CTGF is progressively produced at a likely lower 
concentration and is released as a full size protein of 38kD, as shown in our western-blots. It has been 
further shown that CTGF can be proteolytically modified to generate polypeptides with different affinity 
for receptors and biological properties. The discrepancies that we observed in the two experimental 
settings can be therefore explained by different concentrations and biological properties of CTGF. In these 
conditions, further comparisons of the relative activity of recombinant and native secreted CTGF was not 
considered relevant to this experiment aiming only at evaluating whether VIC are able to respond to 
CTGF, which we proved to be the case.  





1. Mechanical stress activates RhoC promoting, via ROCK, pro-fibrotic genes expression. 
2. Mechanical stress also activates MEK/Erk1/2, independently of RhoC and ROCK. 
3. MRTFA translocates to the nucleus, a process dependent on RhoC and Erk1/2 activation. 
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The mitral valve is a complex multilayered structure populated by fibroblast-like cells, valvular 
interstitial cells (VIC) which are embedded in an extracellular matrix (ECM) scaffold and are 
submitted to the mechanical deformations affecting valve at each heartbeat, for an average of 
40 million times per year. Myxomatous mitral valve (MMV) is the most frequent heart valve 
disease characterized by disruption of several valvular structures due to alterations of their ECM 
preventing the complete closure of the valve resulting in symptoms of prolapse and 
regurgitation. VIC and their ECM exhibit reciprocal dynamic processes between the mechanical 
signals issued from the ECM and the modulation of VIC phenotype responsible for ECM 
homeostasis of the valve. Abnormal perception and responsiveness of VIC to mechanical stress 
may induce an inappropriate adaptative remodeling of the valve progressively leading to MMV. 
To investigate the response of human VIC to mechanical strain and identify the molecular 
mechanisms of mechano-transduction in these cells, a cyclic equibiaxial elongation of 14% at 
the cardiac frequency of 1.16 Hz was applied to VIC by using a Flexercell-4000T™ apparatus for 
increasing time (from 1h to 8h). We showed that cyclic stretch induces an early (1h) and 
transient over-expression of TGF2 and SMA. CTGF, a profibrotic growth factor promoting the 
synthesis of ECM components, was strongly induced after 1 and 2 h of stretching and still 
upregulated at 8 h. The mechanical stress-induced CTGF up-regulation was dependent on RhoC, 
but not RhoA, as demonstrated by siRNA-mediated silencing approaches, and further supported 
by evidencing RhoC activation upon cell stretching and suppression of cell response by 
pharmacological inhibition of the effector ROCK1/2. It was also dependent on the MEK/Erk1/2 
pathway which was activated by mechanical stress independently of RhoC and ROCK. Finally, 
mechanical stretching induced the nuclear translocation of myocardin related family factor 
MRTF-A which forms a transcriptional complex with SRF to promote the expression of target 
genes, notably CTGF. Treatment of stretched cultures with inhibitors of the identified pathways 
(ROCK1/2, MEK/Erk1/2, MRTF-A translocation) blocked CTGF overexpression and abrogated the 
increased MRTF-A nuclear translocation. CTGF is up-regulated in many pathological processes 
involving mechanically challenged organs, promotes ECM accumulation and is considered as a 
hallmark of fibrotic diseases. Pharmacological targeting of MRTF-A by newly developed 
inhibitors may represent a relevant therapy for MMV. 
 
 





The role of the heart valves is to ensure the unidirectional blood flow during the cardiac cycle by 
opening and closing motion. They possess the remarkable ability to withstand the mechanical 
forces they experience at each cardiac cycle: tension when closed to prevent retrograde flow, 
flexion during closing and opening, and shear stress due to blood flow [1]. Like the other cardiac 
valves, the atrio-ventricular mitral valve is a complex multilayered structure, each layer 
containing specific extracellular matrix (ECM1) components. The fibrosa, the thickest layer of the 
valve on the ventricular side, is mostly composed of dense and aligned collagen fibers that 
provide most of the tensile strength to the leaflet. The spongiosa, a glycosaminoglycans and 
proteoglycans enriched layer, provides mitral valve with its resistance to compression while the 
atrialis, a layer rich in elastin, confers its elasticity. Mitral valve is populated by fibroblast-like 
cells, named valvular interstitial cells (VIC), which are in close contact with the ECM and are 
therefore submitted to the mechanical deformations affecting valve at each heartbeat, for an 
average of 40 million times per year. The phenotype of VIC is regulated by the various signals 
issued from their environment and, in turn, VIC are responsible for the homeostasis and 
remodeling of the valvular ECM, forming intermingled interactive loops between the ECM 
properties, the mechanical constraints affecting valves and the phenotype of VIC [2].  
Myxomatous mitral valve (MMV) is the most frequent heart valve disease, affecting 2-3% of the 
population[3]. Its prevalence increases markedly after the age of 65 years and it is becoming a 
health burden due to the current extending life expectancy in the industrialized countries [4]. 
MMV is characterized by disruption of several valvular structures (enlarged leaflet, annular 
dilatation, elongated/ruptured chordae), an increased density of Ki-67 positive proliferating cells 
and alterations of the ECM, notably an accumulation and disorganization of collagen fibers in 
the fibrosa, a fragmentation of elastic fibers, an expansion of the spongiosa by a loose ECM 
enriched in proteoglycans [5].  
Modifications of the physiological valvular geometry linked to a progressive inappropriate ECM 
remodeling result in abnormal perception and responsiveness of VIC to mechanical stress 
_____________________________________________________________________________ 
1 Abbreviations: COL1A1 :  1 chain of type I collagen; CTGF/CCN2: connective tissue growth 
factor; ECM: extracellular matrix; F-actin: fibrillary-actin; GAGs: glycosaminoglycans; G-actin: 
globular actin; GAP: GTPases activating proteins; GDI: guanine nucleotide dissociation inhibitors; 
GEF; guanine nucleotide exchange factors; GTP: guanosine tri-phosphate; MMP: matrix 
metalloproteinase; MMV: myxomatous mitral valve; MRTF-A: Myocardin related Transcription 
Factor A; PAI-1: plasminogen activator inhibitor 1; PGs: proteoglycans; -SMA :  smooth 
muscle actin ; SMC: smooth muscle cells; SOD 1: superoxide dismutase 1; TIMP1: tissue inhibitor 
1 of MMP; VIC: valvular interstitial cells. 
4 
 
which, in turn, may lead to a vicious circle and contribute to perpetuation of the disease 
[2].These structural defects prevent the complete closure of the valve causing symptoms of 
prolapse and regurgitation which ultimately lead to heart failure and to a significant morbidity 
and mortality [6, 7]. Besides surgery for the severe forms of MMV, the medical therapies used in 
some patients aim at limiting the left ventricular remodeling but do not address the primary 
mechanism of mitral valve dysfunction. 
Although MMV has been largely described at clinical, functional and histological levels, the 
cellular and molecular mechanisms underlying the pathological ECM remodeling are still elusive. 
Pathogenesis of MMV has been related to biological mediators such as serotonin [8, 9], 
angiotensin II [10] and activation of the TGF pathway [11, 12]. Mechanistic knowledge was also 
gained from studies of the syndromic forms of MMV, such as Marfan and Loeys-Dietz 
syndromes [13, 14] characterized by an activated TGF signaling. It is currently increasingly 
recognized that mechanical stress is one major etiological factor underlying soft connective 
tissue remodeling, including the pathological remodeling observed in MMV. Various in vitro and 
ex vivo studies have investigated the phenotypic response to mechanical loading of human and 
animal VIC. Altogether, they show an activation of VIC towards a SMC phenotype, an increased 
synthesis of PGs, GAGs and collagen, as well as increased expression and activity of proteolytic 
enzymes [15-19]. Most of these studies were however performed on cells and tissues from 
aortic valve. Extrapolating results from aortic to mitral valve seems only partly relevant since 
dysregulated aortic VIC tend to express an osteogenic-like phenotype while MMV are weakened 
due to a massive deposition of PGs and are characterized by the expression of cartilage markers 
[20] and a loss of mechano-competent layered structure.  
Although these studies clearly demonstrated that mechanical stress plays a fundamental role in 
valvular ECM remodeling, the mechanisms of transduction of mechanical cues into biochemical 
signals that drive tissue remodeling have been little investigated in human mitral VIC. Our work 
aimed at identifying genes modulated by cyclic mechanical deformations and the downstream 
signaling pathways involved in their regulation. These data should provide a better 
understanding of the mechanisms driving MMV progression and potentially uncover new 




2. MATERIAL AND METHODS 
2.1 Cells and culture reagents 
Isolation of interstitial cells (VIC) was performed by outgrowth from explants of posterior 
segment (P2) of human healthy mitral valves from 3 donors as previously described [11]. The 
study was approved by the Ethics Committee of Liege University Hospital (B70720071262). VIC 
cultures were amplified in EBM-2 medium containing 5% FBS (Lonza) at 37°C in 95% air, 5% CO2. 
Cells were used at passage 3–8 and displayed the typical elongated morphology with expanding 
thin cytoplasmic processes (Fig S1).  
2.2 Reagents and chemicals: 
Western-blot and immunohistology were performed with antibodies against CTGF (Santa Cruz, 
sc-14939), RhoA (Santa Cruz, sc-418), RhoC (Santa Cruz, sc-26480 and Cell Signaling Technology 
#3430), Rac1 (BD Biosciences 610651), MRTF-A (Santa Cruz, sc-398675), p-Erk1/2 (Sigma, 
M8159), Erk1/2 (Sigma, M-5670), α-tubulin (Sigma, T6199) and YAP (Santa Cruz H125). 
Secondary antibody Alexa Fluor 555 goat anti-mouse IgG (Invitrogen, A21424) was used for 
immunofluorescence and secondary horseradish peroxydase-conjugated rabbit anti-mouse 
(Dako, P0260), rabbit anti-goat (Dako, P0449) and swine anti-rabbit (Dako, P0217) were used for 
western-blot. Phalloïdin-FITC (Sigma, P-5282) was used for staining fibrillar actin and DAPI (Life 
Technologies, D1306) for nuclear staining. Recombinant human CTGF was from Gibco 
(PHG0286). Primers used for qRT-PCR are listed in supplemental material (Table S1). The 
following pharmacologic inhibitors were used: Y27632 (Selleckchem, S1049), a potent and 
selective inhibitor of ROCK1/2 competing with ATP for binding to the catalytic site [21]; U0126 
(Calbiochem, 662005), a specific inhibitor of MEK1 and MEK2 antagonizing the AP-1 
transcriptional activity [22]; CCG-1423 (Calbiochem, 555558), an inhibitor preventing the 
binding of importin /1 to MRTFA and its nuclear translocation [23]. 
2.3 Cyclic stretching of VIC 
150 000 cells were seeded in EBM-2 medium supplemented with 2% FBS in a 2 cm Ø glass ring 
placed in the center of the well (to ensure a homogeneous deformation) of a 6-well Bioflex plate 
with flexible silicone rubber bottoms coated with type I collagen (Flexcell International Corp). 
After 24 hours of attachment, cells were starved for 24 hours in EBM-2 medium supplemented 
with 0.1% FBS. They were then exposed to continuous cycles of equibiaxial stretch (14%) 
/relaxation for indicated times at the cardiac frequency of 70 cycles/minute by a computer-
assisted vacuum pump (Flexercell 4000™, Flexcell International Corp.). When indicated, 




2.4 CTGF-treated VIC 
Subconfluent monolayers of VIC on plastic were treated with 30 ng/ml recombinant human 
CTGF for 48h and then lyzed for qRT-PCR.  
2.5 siRNA transfection 
21-nucleotides long siRNAs (desalted, deprotected and PAGE purified) were from Eurogentec 
(Liège, Belgium). The sequences of the siRNAs targeting RhoA (siRhoA), RhoC (siRhoC), Cdc42 
(siCdc42) and Rac1 (siRac1) and that of the control siRNA (siScr) were designed in our laboratory 
and validated for their specificity and efficacy [24, 25]. They are listed in supplemental material 
(Table S2). Each pair of oligoribonucleotides was annealed at a concentration of 20 μM in 50 
mM NaCl, 1mM EDTA, 10 mM TrisHCl pH 7.5. Calcium phosphate mediated transfection of 
siRNAs was performed overnight (14-16 h) on subconfluent cells at a final concentration of 20 
nM. Cells were washed twice with PBS and maintained in EBM-2 medium containing 5% FBS. 
After 24 hours, cells were trypsinized and seeded on the Bioflex plates, this step being defined 
as time 0 post-transfection.  
2.6 RNA extraction and purification 
Total RNA was purified from VIC cultures using the High Pure RNA isolation kit (Roche Molecular 
Biochemical) following the manufacturer’s instructions and quantified by a Nanodrop 1000 
spectrophotometer (Isogen Life Science). 
2.7 Real time quantitative PCR 
1 µg of total RNA was reversed transcribed using SuperScript III Reverse Transcriptase 
(Invitrogen) and oligodT. Real time qPCR was performed in a final volume of 25 µl containing 2.5 
µl of cDNA (corresponding to 10 ng of total RNA), 300 nM of each primer and 12.5 µl of the 
qPCR MasterMix Plus for SYBR® green (Eurogentec) in the StepOneTM Real-Time PCR system 
(Applied Biosystems). The results were analyzed with the StepOneTM Software and normalized 
to the GAPDH transcript using the 2Ct method. Results are expressed relative to the values 
measured in control static samples taken as 1. 
2.8 Proteins extraction and western-blot 
Cells were lysed in Laemmli buffer and the extracts were denatured at 90°C. Proteins were 
separated by SDS-PAGE and transferred to a PVDF Transfer Membrane (NEN Life Science 
Products). Membranes were then blocked for 1 hour with 3 % dry milk in PBS-0.05 % Tween 20 
and incubated overnight with the primary antibody. Membranes were then washed three times, 
incubated with the secondary horseradish peroxydase-conjugated antibody for 1 h, and 
revealed by using the ECL kit (Amersham Biosciences). Western blots were quantified with 
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ImageQuant™ LAS 4000 and reported to αTubulin used as control protein loading. Results are 
expressed relative to the values measured in static non-treated VIC taken as 1. 
2.9 RhoC activity assay 
The assay was carried out as previously described [26]. Briefly, cells were chilled on ice and 
lysed in ice-cold buffer containing 0.5% Triton X-100, 25 mM HEPES pH 7.3, 150 mM NaCl, 5mM 
MgCl2, 0.5 mM EGTA, 4% glycerol, 0.1 mM AEBSF, 4 µg/ml aprotinin. Lysates were centrifuged 
for 6 minutes at 20000 g. For each time point, the lysates from 6 Flexercell wells were pooled to 
securely measure the active RhoC. A small aliquot of each supernatant was immediately 
denatured in SDS-PAGE lysis buffer to measure the total RhoC content by Western blotting and 
the supernatants were immediately frozen in liquid nitrogen and stored at -80°C until use for 
pull-down assays. Supernatants were incubated for 30 minutes with 30 µg of GST-RBD protein 
containing the RhoC binding region of Rhotekin affinity linked to glutathione-Sepharose beads. 
The beads were washed 4 times in lysis buffer and boiled in 60µl SDS-PAGE lysis buffer. One 
third of the lysate was separated on SDS-PAGE gel and the RhoC content, corresponding to the 
active RhoC, was measured by Western blotting. 
2.10 MRTF-A nuclear translocation 
After cyclic stretching for 30 min, cells were washed with PBS and fixed in the Bioflex wells for 
10 min in 4% paraformaldehyde at room temperature. After washing with PBS, cells were 
permeabilized for 5 min at room temperature with 0.01% Triton X-100 in PBS. After blocking 
non-specific sites with 5% BSA in PBS, cells were incubated with an anti-MRTF-A monoclonal 
antibody (1/50) in 1% BSA/PBS overnight at 4°C. Cells were then incubated with Phalloïdin-FITC 
(2 µg/ml) in 1% BSA/PBS for 1 hour and then with a secondary antibody Alexa Fluor 555 goat 
anti-mouse IgG (1/1000) in 1% BSA/PBS for 1 hour. Finally, cells were incubated with DAPI (2.5 
µg/ml) for 5 min at room temperature to stain nuclei and mounted with Aqua-Poly/Mount 
Coverslip Medium (18600; PolySciences). Cells were analyzed by using Nikon Eclipse Ti 
microscope and the NIS-Elements Imaging Software. The total fluorescence was measured in 
each cell delimited by the FITC-phalloïdin staining of the cortical actin and the nuclear 
fluorescence (nf) measured in the nucleus delimited by the DAPI staining. Between 29 and 58 
cells were analyzed per condition. The nuclear translocation of MRTF-A was expressed as the 
percentage of fluorescence associated with the nucleus and cells were distributed into 3 
categories: nf<10%; 20%>nf>10%; nf>20%. 
2.11 Statistics:  
Data were analyzed by using GraphPad Prism 5.0 and were presented as the mean + SEM. 
Statistical analysis was performed by using the Student's t-Test for unpaired samples and the 




3.1 Cyclic stretch increases the expression of TGF2, SMA and CTGF/CCN2 
A cyclic mechanical strain was applied to subconfluent VIC plated onto flexible silicone rubber 
membranes coated with type I collagen (Bioflex) by using a Flexercell-4000T™ apparatus. 
Preliminary experiments using various conditions of cell density seeding, culture medium 
composition, pre-treatment, stretching amplitude, frequency and duration were performed. 
After seeding, spreading and starvation as detailed in Materials and Methods, VIC were 
submitted to a cyclic equibiaxial elongation of 14%, a stretching amplitude remaining in the 
physiological range, at the cardiac frequency of 1.16 Hz for 1, 2, 4 or 8 h in medium 
supplemented with 0.1% FBS. Control cultures were handled in parallel except for the 
mechanical stretching that was omitted (static cultures). Based on previous results from our 
laboratory [11] and data from the literature [for review, see 27], the expression of a panel of 
genes relevant to MMV and mechanobiology was investigated by qRT-PCR.  
While the expression of TGF1 was not modified by stretching at any time point (Fig 1A), the 
mRNA level of TGF2 and SMA was significantly increased after 1 hour of stretching and then 




Fig 1: Mechanical stretching induces TGF2SMA and CTGF overexpression: Expression of 
TGF1 (A), TGF(B), SMA (C) and CTGF(D) was measured by qRT-PCR in VIC submitted to 
mechanical stretching or kept in control static conditions for increasing time. Results are 
expressed in arbitrary units (A.U.) relative to GAPDH taking static cultures at 1h as 1 (n=5 to 11). 
Representative western-blot of the production of CTGF in static (-) and stretched (+) VIC for 
increasing time using tubulin as protein load control (E). Amount of CTGF produced by VIC 
submitted to mechanical stretching compared to control static cultures for increasing time. 
Results are expressed in arbitrary units (A.U.) relative to tubulin taking static cultures at 1h as 1 
(F) (n=3 to 6). * p<0.05; ** p< 0.005, ***p<0.0005. 
CTGF/CCN2 is a matricellular protein. Acting as a growth factor, it promotes ECM accumulation 
and is involved in many fibrotic diseases. In our experimental model, a very significant 
stimulation of CTGF expression was already observed at the mRNA level after 1 and 2 h of 
stretching (Fig 1 C) and persisted until 4 and 8 h with a progressive decline. The protein 
production paralleled the mRNA level with a slight delay as shown by western-blot (Fig 1E & 1F). 
These data clearly identify CTGF as a specific mechano-responsive marker useful to investigate 
the molecular mechanisms driving the response of VIC to mechanical deformations. 
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Among the other tested genes, TGFβ3, COL1A1, SOD1 and MMP1, none was found significantly 
modulated in our experimental conditions (Table S3).  
3.2 The small RhoGTPase RhoC, but not RhoA, is involved in the mechanical stress-induced 
CTGF up-regulation 
The small GTPases of the RhoA family are crucial molecular switches involved in the 
transduction of mechanical signals issued from the extracellular environment and the 
cytoskeleton dynamics. We investigated the involvement of RhoA, RhoC, Rac1 and Cdc42 in the 
mechanical stress-induced up-regulation of CTGF by silencing their expression with siRNAs [21, 
22]. SiRNA for RhoA, RhoC and Rac1 efficiently and specifically silenced their target (Fig 2A). 
Cells transfected with siCdc42 stopped proliferating, detached from their support and were not 
further used. 
In static cells, the basal level of CTGF was reduced by silencing Rac1 and RhoA, while repressing 
RhoC had no effect (Fig 2B, open bars). We then compared the effect of cyclic stretching (black 
bars) to static cultures in each condition. In control cells (siScr), the expression of CTGF was 
increased upon cyclic stretching, as expected (Fig 2 B). Although the basal CTGF expression was 
reduced in siRac1 and siRhoA transfected VIC, its fold induction by stretching was similar to siScr 
cells, or even slightly higher, indicating that Rac1 and RhoA are not involved in the stretch-
induced up-regulation of CTGF. By contrast, cells transfected with siRhoC did not respond 
suggesting a specific implication of RhoC in the regulations triggered by mechanical stretching 
(Fig 2 B). 
To further support the role of RhoC in the transduction of the mechanical signals, we performed 
a pull-down assay which allows measuring the GTP-linked active RhoC. As shown in figure 2C 
and D, an increased proportion of active RhoC was observed after 10 min of stretching. Y27632 
is a specific and potent inhibitor of ROCK1/2 [21], a main effector of RhoA and RhoC acting on 
downstream pathways involved in actin polymerization. It did not modify the basal expression 
of CTGF in static conditions but suppressed the stress-induced CTGF up-regulation, both at the 
mRNA (Fig 2 E) and protein level (Fig 2 F&G). Since RhoA is dispensable in this process (Fig 2B), 




Fig 2: RhoC regulates mechanical stress-induced CTGF expression through ROCK1/2. VIC were 
transfected with siRNAs targeting Rac1 (siRac1), RhoA (siRhoA) or RhoC (siRhoC) or with an 
irrelevant scramble siRNA (siScr) used as a negative control. The efficacy of silencing was 
evaluated by western-blot using antibodies specific to each GTPase. Alpha-tubulin (Tub) was 
used as protein loading control (A). CTGF expression was measured by qRT-PCR in transfected 







arbitrary units (A.U.) relative to GAPDH taking Siscr-static cultures as 1 (n= 3 to 5 separate 
experiments, each performed in triplicate; # p< 0.01, siRhoA or siRac1 vs siScr; ** p< 0.01, * p< 
0.05, stretched vs static) (B). The activation of RhoC was measured by pull-down assay in VIC 
stretched for 5, 10 and 20 min (C). Active RhoC is expressed in arbitrary units (A.U.) relative to 
total RhoC in each condition (n=3) **p<0.01 (D). CTGF expression was measured by qRT-PCR in 
VIC non-treated (NT) or pretreated with Y27632 (5 µM), an inhibitor of of the effector of RhoC, 
ROCK1/2, and stretched for 4h (E). Representative CTGF western-blot of VIC static or stretched 
and treated or not by Y27632. Alpha-tubulin (Tub) was probed as control for protein loading (F). 
Quantification of the CTGF western-blots expressed in arbitrary units (A.U.) relative to alpha-
tubulin taking static non-treated (NT) cultures as 1 (n=3 separate experiments performed in 
duplicate, * p= 0.02) (G).  
3.3 The MEK/Erk pathway is activated by mechanical stress, independently of RhoC and ROCK, 
and participates in the CTGF up-regulation. 
Extracellular signal–regulated kinases (Erk1/2) were evaluated in our experimental model since 
they are key secondary messengers for many signals issued from the extracellular environment. 
A rapid and transient phosphorylation of Erk1/2 was observed already after 5 minutes of 
mechanical stretching (Fig 3A) and returned to basal values after 15 min (not shown). Inhibition 
of MEK, an upstream activator of Erk1/2, by U0126 [22] efficiently suppressed the 
phosphorylation of Erk1/2 in VIC. While this inhibitor did not modify the basal level of CTGF in 
static conditions, it completely abolished its mRNA and protein overexpression upon cyclic 
stretching (Fig 3B-D).  
To evaluate whether the activation of the MEK/Erk pathway was depending on the RhoC/ROCK 
pathway, the phosphorylation of Erk1/2 was measured in VIC transfected with siRhoC and 
submitted to mechanical stretching for 10 min. As shown in fig 3E & F, the level of Erk1/2 
phosphorylation was similar in siRhoC and siScramble transfected cells under stretching 
conditions. In accordance, treatment of stretched VIC with Y27632, a ROCK inhibitor, did not 
impair the activation of Erk 1/2 (Fig 3G and H). These results demonstrate that Erk1/2 pathway 













Fig 3: MEK/Erk1/2 signaling is activated by mechanical stress, independently of RhoC and 
ROCK, and participates to the stress-induced CTGF expression. Representative western blot of 
phospho-Erk1/2 (pErk) in VIC submitted (+) or not (-) to cyclic stretching for 5 and 10 min in 
presence (+) or absence (-) of U0126 (10 µM), a MEK inhibitor (A). CTGF mRNA expression in 
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static and stretched cultures for 4 h in absence (NT) and presence of U0126. Results are 
expressed in arbitrary units (A.U.) relative to GAPDH taking non-treated (NT) static cultures as 1 
(B). Representative western blot of CTGF in static (-) and stretched VIC for 4 h (+) in absence (-) 
and presence (+) of U0126 (C). Quantification of the Western-blots for CTGF expressed in 
arbitrary units (A.U.) relative to alpha-tubulin (Tub) taking static non-treated (NT) cultures as 1 
(D). Representative Western blot of phospho-Erk1/2 (p-Erk) in VIC transfected by a siRNA control 
(siScr) or a siRNA targeting RhoC (siRhoc), static or submitted to cyclic stretching for 10 min. The 
silencing of RhoC is shown in the second row (E). Quantification of p-Erk expressed in arbitrary 
units (A.U.) relative to alpha-tubulin  taking the static-si Scr transfected VIC as 1 (F). (n= 3 
separate experiments performed in duplicate, * p< 0.05). Representative Western-blot of 
phospho-Erk1/2 (p-Erk) in VIC static or submitted to cyclic stretching for 10 min in absence (ctrl) 
or presence of Y27632, a ROCK inhibitor (G). Quantification of p-Erk expressed in arbitrary units 
(A.U.) relative to alpha-tubulin taking the static non-treated VIC as 1 (H) (n=3 experiments). 
 
3.4 Cyclic stretch induces the nuclear translocation of MRTF-A 
As RhoGTPases/ROCK1/2 are crucial regulators of the dynamics of actin-based cytoskeleton, we 
hypothesized that mechanical stretching might stimulate the formation of fibrillar actin by 
recruiting globular actin molecules, which would result in the release of MRTF-A (myocardin-
related transcription factor A) from its complex with globular actin. Once free in the cytoplasm, 
MRTF-A is translocated into the nucleus where it associates with SRF to activate the 
transcription of target genes, notably CTGF. This process was evaluated by immunostaining of 
MRTF-A in static and stretched cells (Fig 4A) and quantification of the nuclear labeling relative to 




Fig 4: Cyclic-stretch induces MRTF-A nuclear translocation. Representative staining of actin 
fibers by FITC-phalloïdin (green), nuclei by DAPI (blue) (left panel), and immune staining of 
MRTF-A (red, right panel) in static and stretched VIC for 30 min. Nuclei with a low MRTF-A 
fluorescence are pointed by an arrowhead and those with a strong MRTF-A fluorescence by an 
asterisk (A). Distribution of cells (in %) according to the nuclear fluorescence (nf) staining for 
MRTF-A relative to the total fluorescence of the cell (%) measured on 58 (static) and 45 
(stretched) cells in 4 separate experiments (***p<0.001) (B).  
In static cultures, more than 40 % of cells had a nucleus containing very low amount of MRTF-A 
(<10 % of the total fluorescence detected per cell) and only 3 % of cells were found to have 
stronger nuclear labeling (>20%). Upon mechanical stretching, the percentages were completely 






In line with our hypothesis, CCG1423, an inhibitor of the MRTF-A nuclear translocation [23], 
suppressed the CTGF up-regulation in stretched cells (Fig 5A, B, C) without affecting its basal 
expression in static cultures.  
Treatment of stretched cultures with the 3 inhibitors shown to block CTGF expression (Y-27632, 




Fig 5. Inhibition of MRTF-A translocation abrogates stretching-induced CTGF overexpression. 
CTGF expression was measured by RT-qPCR in VIC kept static or stretched for 4h after 
pretreatment or not with CCG1423 (2 µM), an inhibitor of MRTF-A nuclear translocation. Results 
are expressed in arbitrary units relative to GAPDH taking the non-treated (NT) static VIC as 1 (A). 
Representative western blot of CTGF in the same conditions (B) and its quantification relative to 
alpha-tubulin (Tub) expressed in arbitrary units taking the static non-treated (NT) VIC as 1(C) 
(n=3 separate experiments performed in duplicate, * p< 0.05). Representative staining by FITC-
phalloïdin to label actin fibers (green), DAPI to label nuclei (blue) (left panel), and MRTF-A (red, 
right panel) in VIC stretched for 30 min after pretreatment with the ROCK1/2 inhibitor Y27632 (5 




(in %) according to the nuclear fluorescence (nf) staining for MRTF-A relative to the total 
fluorescence of the cell (%) measured on 32 (Y27632), 42 (CCG1423) and 29 (U0126) cells in 4 
separate experiments. The two first bars on the left showing static and stretched VIC without 
any treatment are reproduced from figure 4B (E). 
 
3.5 CTGF induces the expression of extracellular matrix genes  
To evaluate if VICs can respond to CTGF, monolayer cultures were treated with recombinant 
human CTGF. After 48h of treatment, the expression of COL1A1, a known CTGF target gene, and 
of fibromodulin was significantly up-regulated (Fig 2A & B).  
 
Fig 6: CTGF promotes ECM genes and its own expression. Expression of COL1A1 (A), 
fibromodulin (B), CTGF (C) and Cyr61 (D) was measured in VIC treated with human recombinant 
CTGF (30ng/ml) for 48h. Results are expressed in arbitrary units (A.U.) relative to GAPDH taking 
the non-treated (NT) VIC as 1. (n=3 independent experiments performed in triplicate) (* p< 0.05, 
** p< 0.01). 
Interestingly, CTGF also induced its own expression and the expression of Cyr61/CCN1, another 
member of the CCN family (Fig 5 C & D). Other genes potentially modulated by CTGF were 
tested, such as PAI-1, TIMP1 and proteoglycans such as versican, biglycan, lumican and decorin. 
None of them was modulated in our experimental setting showing specificity in the response of 




In order to investigate the influence of mechanical strain on the VIC phenotype and to relate it 
to the pathogenesis of MMV, we used a model of cyclic equibiaxial strain. Although this model 
does not reconstitute the complex 3D mechanical environment of the valve in vivo, it allows 
deciphering the cascade of signaling events triggered by mechanical deformation. Silicone 
membranes coated with collagen were used since data from the literature show that mitral VIC 
adhere to collagen through the integrin 21 and that this coupling drives VIC deformation 
when the valvular tissue is strained [28]. We performed preliminary experiments to define the 
optimal regimen of deformation (14%) at the cardiac frequency for maximum induction of 
several genes in human VIC in our experimental setting while remaining below supra-
physiological range [29].  
Mechanical strain has been shown to activate the TGF pathway in many cell types including 
VIC [30, 19]. Furthermore, myxomatous degeneration of the mitral valve is a constant feature in 
patients suffering from connective-tissues disorders related to enhanced TGF- signaling, such 
as Marfan and Loeyts-Dietz syndromes [31, 14]. Our starting experimental strategy was 
therefore to check any regulation of the TGFβ pathways and its potential target genes. While 
TGF1 is the most frequently reported up-regulated or activated member of the TGFfamily by 
mechanical stimuli, we found here that only TGF2 was significantly up-regulated in stretched 
VIC. This up-regulation was rapid and transient. This finding is consistent with our previous in 
vivo study showing an increased TGF2 expression and deposition in human non-syndromic 
MMV leaflets [11], data confirmed later by Thalji [32]. It is worth noting that the activation of 
the TGFdependent Smad 2/3 effector was not increased in our stretched VIC (data not 
shown).-SMA is one of the target genes of the TGF pathway and is considered as a marker of 
the phenotypic activation and transition of fibroblasts into biosynthetically active 
myofibroblasts. Its induction by mechanical strain has been reported in several studies [33] 
mainly performed on aortic valvular cells or tissues [34,35]. In our experimental conditions, the 
expression of -SMA was also rapidly and transiently increased similarly to that of TGF2.  
We showed here that CTGF was significantly up-regulated in VIC upon stretching. CTGF is a 
member of the CCN genes family. It is a regulatory matricellular protein involved in the control 
of a large variety of important biological functions, notably ECM macromolecules synthesis, and 
most often acts as a downstream effector of TGF. It is recognized as mechano-responsive gene 
acting through integrin-mediated signaling [36, 37]. It is up-regulated in many pathological 
processes involving mechanically challenged organs where it promotes ECM accumulation, 
explaining why it is considered as a hallmark of fibrotic diseases [38]. In agreement with our 
findings in this study, CTGF expression was found significantly increased in human MMV tissues 
and could contribute to the ECM remodeling featuring this disease [39, 40]. The capacity of 
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CTGF to induce its own expression and to act as an autocrine growth factor has been shown in 
fibroblasts [41, 42]. When tested by RT-PCR in static monolayer culture, CTGF stimulated its own 
expression also in VIC. The expressions of type I collagen and fibromodulin, a small rich-leucine 
proteoglycan regulating collagen fibrillogenesis, were also induced while other proteoglycans, 
such as decorin, biglycan or versican, were not significantly modified, showing that VIC actually 
respond to CTGF in a quite specific way that does not involve a general activation of 
transcription. However, we did not observe overexpression of collagen or fibromodulin upon 
stretching, although CTGF expression was increased. Several hypotheses can be made to explain 
such apparent discrepancy. Upon stretching, CTGF being only progressively overerexpressed 
and secreted in a large volume of culture medium, its concentration does not reach that used 
for recombinant CTGF. This does not mean, however, that CTGF could not play a significant role 
in vivo where local concentrations of factors secreted in the extracellular microenvironment are 
much higher than those obtained in vitro. A second explanation relates to CTGF itself. The only 
source of recombinant CTGF is a 11 kDa biologically active peptide, of undisclosed sequence and 
location within the full size protein. By contrast, endogenous CTGF is secreted by VIC as a 38 
kDa full size protein that can be further modified or cleaved, processes known to modulate its 
activity [37]. 
 
Small GTPases of the Rho family are known to play a key role in the integrin-mediated 
transduction of mechanical signals into activation of intracellular signaling pathways and 
remodeling of the cytoskeleton [43, 44]. By using very specific siRNA tools targeting each of the 
archetypal Rho family members, we pointed out RhoC as the RhoGTPase involved in the 
transduction of mechanical stimuli in human VIC. The specific role of RhoC was further 
supported by evidencing its activation. While RhoA has been shown to contribute to the 
mechano-transduction and phenotypic regulation in valvular cells, mainly of aortic valve origin, 
it is to our knowledge the first report of the implication of RhoC and not RhoA, in this process 
probably because of the very specific molecular tools that we used. Although some studies 
suggest the redundant roles between RhoA and RhoC, their different modulation by the 
numerous regulatory factors, GEFs, GAPs and GDI, strongly suggests that they play also context- 
and localization-dependent distinct roles [45, 46]. ROCK is a downstream effector of RhoA and 
RhoC. We have demonstrated that its inhibition (using Y27632) abolished the cyclic stretching-
dependent upregulation of CTGF expression, similarly to what is observed upon siRhoC 
depletion. Remarkably, Y27632 does not modify the “basal” expression of CTGF observed in 
static condition, while siRhoA represses it. These data suggest that RhoC regulates cell response 
to mechanical deformation through ROCK, while RhoA would participate to the maintenance of 
a basal level of CTGF expression via another effector [45]. 
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Among the intracellular signaling pathways initiated by mechanical signals, the HIPPO effectors 
YAP and TAZ are involved in mechano-transduction and translocate to the nucleus in Rho- and 
actomyosin tension-dependent manner [47]. We did not observe any increase in nuclear 
labeling of YAP in stretched VIC (data not shown) excluding therefore this pathway in our 
experimental setting. These data are in line with recent publications reporting a functional link 
between YAP and RhoA specifically [48]. We then investigated the alternative pathway of the 
myocardin related family factors, MRTF A/B, which play a critical role as co-factor of SRF-
dependent gene transcription, including CTGF [49]. MRTF-A resides mainly in the cytoplasm as a 
complex with G-actin. Upon RhoGTPases activation, G-actin is recruited to polymerize into F-
actin liberating MRTF-A which is transiently translocated to the nucleus [50]. Nuclear MRTF-A 
forms a transcriptional complex with SRF to promote the expression of target genes, such as 
CTGF [51]. It is worth noting that CTGF, TGF2 and SMA possess SRF binding sites in their 
promoter. Two complementary approaches, pharmacological inhibition of MRTF-A and 
measurement of its nuclear translocation, allowed us to clearly establish that this pathway was 
triggered in VIC by mechanical strain. In support of its potential involvement in MMV 
remodeling, MRTF-A loss-of-function mice have been shown to be resistant to cardiac, skin and 
lung fibrosis [52]. We were however unable to reproducibly evidence an increased ratio of 
fibrillar/globular actin in stretched VIC. This may be related to the very short and transient 
timing of actin polymerization that we could not detect in the experimental configuration of the 
Flexercell. 
 
The MEK/Erk1/2 pathway is another mechano-responsive pathway that we found effectively 
activated in stretched VIC but independently of the RhoC/ROCK axis. It was previously shown 
that Erk-mediated phosphorylation of MRTF-A at Ser98 inhibits the binding of G-actin on the 
MRTF-A regulatory RPEL domain, which promotes its nuclear import [48]. This mechanism was 
not further investigated in our study due to the unavailability of the antibody recognizing p-
Ser98. However, the existence of such mechanism in our model is supported by the observation 
showing that pharmacological inhibition of the MEK/Erk1/2 pathway resulted in the abrogation 
of stretch-induced MRTF-A nuclear translocation and CTGF up-regulation. It is interesting to 
note that increased p-Erk 1/2 was reported in mitral leaflets of patients with fibroelastic 
deficiency [5].  
Our results show for the first time the central role of the axis RhoC/ROCK/MRTF-A which, 
together with MEK/Erk1/2, regulates the induction of a pro-fibrotic phenotype in mitral valvular 
interstitial cells by mechanical strain. A series of MRTF-A inhibitors have been recently 
developed and proved to be potential new therapeutics for treating fibrotic diseases such as 
scleroderma [54]. In view of our original data, it would be worth investigating if the 
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